Bouabdallaoui, Nadia
Tardif, Jean-Claude
Article History
Accepted: 3 May 2021
First Online: 16 July 2021
Declaration
:
: Dr. Bouabdallaoui reports personal fees from AstraZeneca, outside the submitted work. Dr. Tardif reports grants from Amarin; grants and personal fees from AstraZeneca; grants from Ceapro; grants, personal fees, and minor equity interest from DalCor; grants from Esperion; personal fees from HLS Therapeutics; grants from Ionis; personal fees from Pendopharm; grants from REGENXBIO; and grants and personal fees from Sanofi, outside the submitted work. In addition, Dr. Tardif has a patent pending on use of colchicine after myocardial infarction (but he has waived all rights and does not stand to gain financially from the patent).
: This is a review article. Please refer to each cited study for details regarding ethics approval.